Stock A314130 GENOME & COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Genome & Company Stock

Equities

A314130

KR7314130006

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6,560 KRW -2.67% Intraday chart for Genome & Company -4.93% -47.48%
Jan. 24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
2023 Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial CI

Financials

Sales 2022 14.08B 10.24M Sales 2023 14.3B 10.39M Capitalization 176B 128M
Net income 2022 -51.84B -37.69M Net income 2023 -47.47B -34.51M EV / Sales 2022 10.3 x
Net cash position 2022 100B 73M Net cash position 2023 59.82B 43.49M EV / Sales 2023 8.14 x
P/E ratio 2022
-4.74 x
P/E ratio 2023
-3.72 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.47%
More Fundamentals * Assessed data

Chart Genome & Company

Dynamic Chart

Latest news about Genome & Company

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial CI
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors CI
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors CI
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors CI
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors CI
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc CI
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse CI
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index CI
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million. CI
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study CI
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients CI
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001 CI
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm CI
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors CI
More news

Quotes and Performance

1 day-2.67%
1 week-4.93%
Current month-28.31%
1 month-30.66%
3 months-31.95%
6 months-42.86%
Current year-47.48%
More quotes

Highs and lows

1 week
6 550.00
Extreme 6550
7 150.00
1 month
6 550.00
Extreme 6550
9 450.00
Current year
6 550.00
Extreme 6550
13 850.00
1 year
6 550.00
Extreme 6550
21 050.00
3 years
6 550.00
Extreme 6550
57 600.00
5 years
6 550.00
Extreme 6550
95 000.00
10 years
6 550.00
Extreme 6550
95 000.00
More quotes

Managers and Directors - Genome & Company

Managers TitleAgeSince
Han-Su Park CEO
 Chief Executive Officer 51 15-09-23
Ji-Soo Bae FOU
 Founder 53 15-09-23
Young-Jin Seo BRD
 Director/Board Member 44 -
Members of the board TitleAgeSince
Byeong-Geon Lee BRD
 Director/Board Member 67 -
Ji-Soo Bae FOU
 Founder 53 15-09-23
Han-Su Park CEO
 Chief Executive Officer 51 15-09-23
More insiders

Quotes

Date Price Change Volume
24-04-26 6,560 -2.67% 47,562
24-04-25 6,740 -4.13% 111,294
24-04-24 7,030 +0.57% 28,557
24-04-23 6,990 -0.57% 47,693
24-04-22 7,030 +1.88% 37,455

End-of-day quote Korea S.E., April 25, 2024

More quotes

Company Profile

Genome&Company is a company mainly engaged in the research, development, manufacturing and sale of probiotics. Probiotics are mainly used in products including immune oncology therapeutic supplements, dietary supplements, cosmetics and medicines. These products are mainly applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies.
Sector
Biotechnology & Medical Research
Calendar
2024-05-12 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENOME & COMPANY Stock Genome & Company
-47.48% 71.37M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A314130 Stock